-
Something wrong with this record ?
Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study
E. Clemens, L. Broer, T. Langer, AG. Uitterlinden, ACH. de Vries, M. van Grotel, SFM. Pluijm, H. Binder, J. Byrne, EVD. Broeder, M. Crocco, D. Grabow, P. Kaatsch, M. Kaiser, L. Kenborg, JF. Winther, C. Rechnitzer, H. Hasle, T. Kepak, AF. van der...
Language English Country United States
Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2001-01-01 to 1 year ago
Open Access Digital Library
from 2001-01-01
Health & Medicine (ProQuest)
from 2001-01-01 to 1 year ago
- MeSH
- Cisplatin adverse effects MeSH
- Child MeSH
- Genetic Variation genetics MeSH
- Genetic Association Studies methods MeSH
- Internationality * MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Neoplasms drug therapy epidemiology genetics MeSH
- Hearing Loss chemically induced epidemiology genetics MeSH
- Infant, Newborn MeSH
- Ototoxicity epidemiology genetics MeSH
- Child, Preschool MeSH
- Antineoplastic Agents adverse effects MeSH
- Retrospective Studies MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
Ototoxicity is a common side effect of platinum treatment and manifests as irreversible, high-frequency sensorineural hearing loss. Genetic association studies have suggested a role for SNPs in genes related to the disposition of cisplatin or deafness. In this study, 429 pediatric patients that were treated with cisplatin were genotyped for 10 candidate SNPs. Logistic regression analyses revealed that younger age at treatment (≤5 years vs >15 years: OR: 9.1; 95% CI: 3.8-21.5; P = 5.6 × 10-7) and higher cumulative dose of cisplatin (>450 vs ≤300 mg/m2: OR: 2.4; 95% CI: 1.3-4.6; P = 0.007) confer a significant risk of ototoxicity. Of the SNPs investigated, none of them were significantly associated with an increase of ototoxicity. In the meta-analysis, ACYP2 rs1872328 (OR: 3.94; 95% CI: 1.04-14.03; P = 0.04) and SLC22A2 rs316019 (OR: 1.46; 95% CI: 1.07-2.00; P = 0.02) were associated with ototoxicity. In order to increase the understanding of the association between SNPs and ototoxicity, we propose a polygenic model, which takes into account multiple interacting genes of the cisplatin pathway that together confer an increased risk of ototoxicity.
Aarhus University Hospital Department of Pediatrics Aarhus University Hospital Aarhus Denmark
Boyne Research Institute Drogheda Ireland
Danish Cancer Society Research Center Copenhagen Denmark
Department of Children Hemato Oncology Motol University Hospital Prague Prague Czech Republic
Department of Clinical Medicine Faculty of Health Aarhus University Aarhus Denmark
Department of Internal Medicine Erasmus Medical Center Rotterdam The Netherlands
Department of Neurooncology Istituto Giannina Gaslini Genova Italy
Department of Pediatric Hematology and Oncology VU Medical Center Amsterdam The Netherlands
Department of Pediatric Oncology Academic Medical Center Amsterdam Amsterdam The Netherlands
Department of Pediatric Oncology Erasmus MC Sophia Children's Hospital Rotterdam The Netherlands
Institute of Social and Preventive Medicine University of Bern Bern Switzerland
Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012761
- 003
- CZ-PrNML
- 005
- 20210507104848.0
- 007
- ta
- 008
- 210420s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41397-019-0113-1 $2 doi
- 035 __
- $a (PubMed)31666714
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Clemens, Eva $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. e.clemens@erasmusmc.nl $u Department of Pediatric Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands. e.clemens@erasmusmc.nl
- 245 10
- $a Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study / $c E. Clemens, L. Broer, T. Langer, AG. Uitterlinden, ACH. de Vries, M. van Grotel, SFM. Pluijm, H. Binder, J. Byrne, EVD. Broeder, M. Crocco, D. Grabow, P. Kaatsch, M. Kaiser, L. Kenborg, JF. Winther, C. Rechnitzer, H. Hasle, T. Kepak, AF. van der Kooi, LC. Kremer, J. Kruseova, CE. Kuehni, H. van der Pal, R. Parfitt, D. Deuster, P. Matulat, C. Spix, A. Tillmanns, WJE. Tissing, L. Maier, A. Am Zehnhoff-Dinnesen, O. Zolk, MM. van den Heuvel-Eibrink, PanCareLIFE consortium
- 520 9_
- $a Ototoxicity is a common side effect of platinum treatment and manifests as irreversible, high-frequency sensorineural hearing loss. Genetic association studies have suggested a role for SNPs in genes related to the disposition of cisplatin or deafness. In this study, 429 pediatric patients that were treated with cisplatin were genotyped for 10 candidate SNPs. Logistic regression analyses revealed that younger age at treatment (≤5 years vs >15 years: OR: 9.1; 95% CI: 3.8-21.5; P = 5.6 × 10-7) and higher cumulative dose of cisplatin (>450 vs ≤300 mg/m2: OR: 2.4; 95% CI: 1.3-4.6; P = 0.007) confer a significant risk of ototoxicity. Of the SNPs investigated, none of them were significantly associated with an increase of ototoxicity. In the meta-analysis, ACYP2 rs1872328 (OR: 3.94; 95% CI: 1.04-14.03; P = 0.04) and SLC22A2 rs316019 (OR: 1.46; 95% CI: 1.07-2.00; P = 0.02) were associated with ototoxicity. In order to increase the understanding of the association between SNPs and ototoxicity, we propose a polygenic model, which takes into account multiple interacting genes of the cisplatin pathway that together confer an increased risk of ototoxicity.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a protinádorové látky $x škodlivé účinky $7 D000970
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a cisplatina $x škodlivé účinky $7 D002945
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genetické asociační studie $x metody $7 D056726
- 650 _2
- $a genetická variace $x genetika $7 D014644
- 650 _2
- $a nedoslýchavost $x chemicky indukované $x epidemiologie $x genetika $7 D034381
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a novorozenec $7 D007231
- 650 12
- $a internacionalita $7 D038622
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a nádory $x farmakoterapie $x epidemiologie $x genetika $7 D009369
- 650 _2
- $a ototoxicita $x epidemiologie $x genetika $7 D000081015
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Broer, Linda $u Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
- 700 1_
- $a Langer, Thorsten $u Department of Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany
- 700 1_
- $a Uitterlinden, André G $u Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
- 700 1_
- $a de Vries, Andrica C H $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands $u Department of Pediatric Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands
- 700 1_
- $a van Grotel, Martine $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
- 700 1_
- $a Pluijm, Saskia F M $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
- 700 1_
- $a Binder, Harald $u German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany $u Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany
- 700 1_
- $a Byrne, Julianne $u Boyne Research Institute, Drogheda, Ireland
- 700 1_
- $a Broeder, Eline van Dulmen-den $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands $u Department of Pediatric Hematology and Oncology, VU Medical Center, Amsterdam, The Netherlands
- 700 1_
- $a Crocco, Marco $u Department of Neurooncology, Istituto Giannina Gaslini, Genova, Italy
- 700 1_
- $a Grabow, Desiree $u German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
- 700 1_
- $a Kaatsch, Peter $u German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
- 700 1_
- $a Kaiser, Melanie $u German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
- 700 1_
- $a Kenborg, Line $u Danish Cancer Society Research Center, Copenhagen, Denmark
- 700 1_
- $a Winther, Jeanette F $u Danish Cancer Society Research Center, Copenhagen, Denmark $u Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
- 700 1_
- $a Rechnitzer, Catherine $u Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
- 700 1_
- $a Hasle, Henrik $u Aarhus University Hospital, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
- 700 1_
- $a Kepak, Tomas $u University Hospital Brno, Brno, Czech Republic, & International Clinical Research Center (FNUSA-ICRC), Brno, Czech Republic
- 700 1_
- $a van der Kooi, Anne-Lotte F $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands $u Department of Obstetrics and Gynecology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands
- 700 1_
- $a Kremer, Leontien C $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands $u Department of Pediatric Oncology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Kruseova, Jarmila $u Department of Children Hemato-Oncology, Motol University Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Kuehni, Claudia E $u Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- 700 1_
- $a van der Pal, Heleen $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands $u Department of Pediatric Oncology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Parfitt, Ross $u Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany
- 700 1_
- $a Deuster, Dirk $u Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany
- 700 1_
- $a Matulat, Peter $u Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany
- 700 1_
- $a Spix, Claudia $u German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
- 700 1_
- $a Tillmanns, Amelie $u Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany
- 700 1_
- $a Tissing, Wim J E $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands $u Department of Pediatric Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- 700 1_
- $a Maier, Lara $u Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University Medical Center, Ulm, Germany
- 700 1_
- $a Am Zehnhoff-Dinnesen, Antoinette $u Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany
- 700 1_
- $a Zolk, Oliver $u Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University Medical Center, Ulm, Germany
- 700 1_
- $a van den Heuvel-Eibrink, Marry M $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
- 710 2_
- $a PanCareLIFE consortium
- 773 0_
- $w MED00008068 $t The pharmacogenomics journal $x 1473-1150 $g Roč. 20, č. 2 (2020), s. 294-305
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31666714 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507104845 $b ABA008
- 999 __
- $a ok $b bmc $g 1651011 $s 1133140
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 20 $c 2 $d 294-305 $e 20191031 $i 1473-1150 $m Pharmacogenomics journal $n Pharmacogenomics J $x MED00008068
- LZP __
- $a Pubmed-20210420
